Stage is a prognostic factor for surgically treated patients with early-stage lip cancer for whom a ‘wait and see’ policy in terms of neck status has been implemented

Eskıızmır, Görkem; Ozgur, Emre; Karaca, Gökhan; Temız, Peyker; Yanar, N Hacioglu; Özyurt, Beyhan Cengiz

doi:10.1017/s0022215117001669

Cited by 8 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main indication for the elective neck dissection in head and neck cancer is the presence of the risk of lymph node metastases more than 20% (Shah & Gil, ). Thus, in many clinics, surgery of the primary tumor with “wait and see” policy in terms of neck treatment is the most common treatment in the early‐stage lip cancer (Eskiizmir et al, ; Rena et al, ). In a recent meta‐analysis of the literature about the early‐stage lip cancer with N 0 neck, the rate of occult lymph node metastases was reported as 17% of the patients who underwent elective neck dissection.…”

Section: Discussionmentioning

confidence: 99%

Lip cancer: Reconsidering the at‐risk patients with pathological assessment

Ant¹,

Kılıç²,

Baltu³

et al. 2019

Oral Diseases

View full text Add to dashboard Cite

Objectives This study was aimed to overview the treatment protocols of lip cancer and find out a cutoff point of tumor diameter and depth of invasion (DOI) for the survival parameters. Materials and Methods One hundred and ninety‐one patients with lip SCC were studied. Results The average age of the patients was 62 years. Among 191 patients, 82.7% of the patients were men, 96.4% of them had lower lip cancer, and 84% were staged as early (pT1, pT2). Primary tumor excision with neck dissection was applied to 62.3% of the patients. Lymph node metastases rate was found to be 11%, and recurrence rate was 6.3%. There was statistically significant difference in between the tumor diameters and DOI values of patients with and without metastasis, and recurrence (p < 0.01, p < 0.05, respectively). Regarding to the lymph node metastasis, the optimal cutoff point was found to be 7.5 mm for DOI and 21.5 mm for tumor diameter. Regarding to the recurrence, the optimal cutoff point was found to be 7.5 mm for DOI and 24.5 mm for tumor diameter. Conclusion T2 lip cancer patients also seem to be in at‐risk group for metastasis and recurrence. As a conclusion, elective neck dissection and frequent follow‐up are recommended for these early‐stage lip cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Lip cancer: Reconsidering the at‐risk patients with pathological assessment

Ant¹,

Kılıç²,

Baltu³

et al. 2019

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…Although most primary tumors can be treated with brachytherapy alone (provided that there is no bone involvement), elective cervical treatment should be considered in lip tumors larger than 10 mm or with skin or commissural involvement or with a pattern of tumor invasion or in the case of a tumor developing from the labial mucosa [28,29]. However, the management of the clinical cN0 neck in the SCC of the lip is controversial, with some authors suggesting elective neck dissection in almost all cases [11,30], whereas others prefer a wait-and-see management [31]. More recently, a sentinel node biopsy (SNB) procedure was proposed, with a high rate of sentinel lymph node (SLN) localization (range: 90-93%), and rates of micrometastases ranging from 7.1 to 16.6% [32].…”

Section: Discussionmentioning

confidence: 99%

Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis

Ayachy

Sun

et al. 2021

Cancers

View full text Add to dashboard Cite

Purpose: Lip carcinoma represents one of the most common types of head and neck cancer. Brachytherapy is a highly effective therapeutic option for all stages of lip cancers. We report our experience of pulsed dose rate brachytherapy (PDR) as treatment of lip carcinoma. Methods and Materials: this retrospective single center study included all consecutive patients treated for a lip PDR brachytherapy in our institution from 2010 to 2019. The toxicities and outcomes of the patients were reported, and a retrospective quality of life assessment was conducted by phone interviews (FACT H&N). Results: From October 2010 to December 2019, 38 patients were treated in our institution for a lip carcinoma by PDR brachytherapy. The median age was 73, and the majority of patients presented T1-T2 tumors (79%). The median total dose was 70.14 Gy (range: 60–85 Gy). With a mean follow-up of 35.4 months, two patients (5.6%) presented local failure, and seven patients (19%) had lymph node progression. The Kaplan–Meier estimated probability of local failure was 7.2% (95% CI: 0.84–1) at two and four years. All patients encountered radiomucitis grade II or higher. The rate of late toxicities was low: three patients (8.3%) had grade II fibrosis, and one patient had grade II chronic pain. All patients would highly recommend the treatment. The median FACT H&N total score was 127 out of 148, and the median FACT H&N Trial Outcome Index was 84. Conclusions: This study confirms that an excellent local control rate is achieved with PDR brachytherapy as treatment of lip carcinoma, with very limited late side effects and satisfactory functional outcomes. A multimodal approach should help to improve regional control.

show abstract

“…8,9 A study by Eskiizmir et al in this month's issue concludes that tumour stage is an important determining factor affecting prognosis in surgically treated patients with early-stage lip cancer for whom a 'watch and wait' policy for neck status has been implemented. 10 Finally, two articles in this month's issue report on the successes and complications of paediatric cochlear implantation. Mulwafu et al report on the first four cases of cochlear implantation in Malawi.…”

mentioning

confidence: 99%

“…, 9 A study by Eskiizmir et al . in this month's issue concludes that tumour stage is an important determining factor affecting prognosis in surgically treated patients with early-stage lip cancer for whom a ‘watch and wait’ policy for neck status has been implemented 10 …”

mentioning

confidence: 99%